With partner Roche/Genentech Inc. filing for approval of T-DM1 on Aug. 27, ImmunoGen Inc. is trying to broaden the story to its own internal pipeline. While the biotech stands to get more than $15 million in milestone payments once the cancer drug is approved in the U.S. and Europe, it believes its pipeline candidates could hold even more value for the company.
“People see antibody-drug conjugates as a whole new approach to treating cancer,” said ImmunoGen CEO Dan Junius in an interview....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?